- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹43 Cr4,315th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet.
- Shares changed
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 12 Aug 2026
- −2.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 12 Aug 2026
- −2.5%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 4 Jun 2026
- 0.00
- Volume, BSEVolume. Shares traded on the last trading day.
- 3,530
Prism Medico and Pharmacy board of directors
At the end of the quarter to Jun 2026, as the company filed it; changes since are in its announcements.Their trades in its shares
- Company Secretary and Compliance OfficerSAMEER GUPTA
4 directors2 independent1 executive1 non-executive
- DAVENDER SINGHNon-executive · joined Dec 2021 · 55 months as independent · 1 listed board · 1 committee seat, 1 as chair
- PARDEEP KUMARIndependent · joined Dec 2021 · 55 months as independent · 1 listed board · 1 as independent · 1 committee seat
- DINESH KUMARIndependent · joined Aug 2023 · 35 months as independent · 1 listed board · 1 as independent · 1 committee seat
- SAKSHI LALLERExecutive · joined May 2023 · 38 months as independent · 1 listed board
An independent director has no business or family tie to the company, its promoters or its managers beyond the seat. Listed boards counts the boards of listed companies the director sits on, this one included, and "as independent" how many of those seats are independent ones. Committee seats are audit and stakeholder committee seats across those companies. Months as independent is filed for independent directors only, whose terms the rules cap. Disqualified is the company's own mark that a director may not serve under company law.
Committees and meetings
Who sits on each, and how often they met.Board meeting notices and outcomes
Board
- 28 May 20264 of 4 present2 independent · 16 days in between
- 11 May 20264 of 4 present2 independent · 5 days in between
- 5 May 20264 of 4 present2 independent · 70 days in between
- 23 Feb 20264 of 4 present2 independent · 9 days in between
1 earlier meeting
- 13 Feb 20264 of 4 present2 independent
Audit Committee
Chair DAVENDER SINGH
PARDEEP KUMAR, DINESH KUMAR
- 28 May 20263 of 3 present2 independent · 16 days in between
- 11 May 20263 of 3 present2 independent · 86 days in between
- 13 Feb 20263 of 3 present2 independent
Nomination and remuneration committee
Chair DAVENDER SINGH
PARDEEP KUMAR, DINESH KUMAR
- 28 May 20263 of 3 present2 independent · 103 days in between
- 13 Feb 20263 of 3 present2 independent
Stakeholders Relationship Committee
Chair DAVENDER SINGH
PARDEEP KUMAR, DINESH KUMAR
- 13 Feb 20263 of 3 present2 independent
Meetings in the quarter filed and the one before it. The days in between are as the company files them, neither meeting's day counted; the rules allow at most 120. A quorum is the least number of members who must attend for the meeting to decide anything.
Statutory auditor
Named in the results for the quarter to Mar 2026.
- GARG MENDIRATTA & ASSOCIATESPeer-review certificate valid to Dec 2027
1 earlier auditor
- Harjeet Parvesh and CompanyNamed in the filing for the quarter to Mar 2025
A statutory auditor checks the company's accounts and signs its results. Peer review is the accountants' institute's check of an audit firm's own work, which a listed company's auditor must hold a valid certificate of.
Prism Medico and Pharmacy AGM and shareholder votes
Each resolution, how the votes went, and how institutions voted apart from the promoters. A postal ballot is a vote by post or online, held without a meeting.Prism Medico and Pharmacy share news and announcements
Annual general meeting, 19 Sep 2026
4,220 shareholders on the register on 12 Sep 2026; present: 0 promoters and 24 others; votes counted by MAST RAM CHECHI / M.R. CHECHI AND ASSOCIATES.The company's voting result (opens in a new tab)
To receive, consider and adopt the Standalone Financial Statements of the company for the financial year ended 31st March, 2026 together with the Reports of the Board of Directors and Auditors thereon.MoreLess
Ordinary100.00% for0.00% againstAgainst: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 100.00% · promoters 0.00% · institutions 0.00% · other public 100.00%
- To appoint a Director in place of Mr. Davender Singh (DIN: 09447213), who retires by rotation and being eligible, offers himself for re-appointment.OrdinaryPromoters have an interest in it100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 100.00% · promoters 0.00% · institutions 0.00% · other public 100.00%
- To re-appoint M/s. Garg Mendiratta and Associates, Chartered Accountants as the statutory auditors of the company and fix their remuneration.Ordinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 100.00% · promoters 0.00% · institutions 0.00% · other public 100.00%
To appoint M/S. SDK & Associates, Practicing Company Secretaries as the Secretarial Auditors of the Company for a period of five financial years from financial year 2026-2027 to financial year 2030-2031.MoreLess
Ordinary100.00% for0.00% againstAgainst: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 100.00% · promoters 0.00% · institutions 0.00% · other public 100.00%
- To approve variation in the objects of the Preferential Issue and in the utilisation of the proceeds thereof, as approved by the members at the Extraordinary General Meeting held on March 20, 2026.SpecialPromoters have an interest in it99.99% for0.01% against
Against: promoters 0.00% · institutions 0.00% · other public 0.01%
Turnout: all 100.00% · promoters 0.00% · institutions 0.00% · other public 100.00%
- To approve the investment of funds in the securities of M/s. Infuze Well Private Limited under Section 186 of the Companies Act, 2013.Special100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 100.00% · promoters 0.00% · institutions 0.00% · other public 100.00%
- To approve material related party transaction — strategic investment by way of subscription to equityshares of M/s. Infuze Well Private Limited.Ordinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 100.00% · promoters 0.00% · institutions 0.00% · other public 100.00%
- To approve the related party transactions.OrdinaryPromoters have an interest in it100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 100.00% · promoters 0.00% · institutions 0.00% · other public 100.00%
For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.
Investor complaints and compliance
Quarter by quarter.
Investor complaints received and resolved, the company's own count
- Received
- Resolved
Open at the quarter's end
- The board is made up as the listing rules require
- Yes
- The board has a regular chairperson
- No
- The company has a risk management committee
- No
- The chair is related to the managing director
- No
- The filing has a part on fines and penalties
- No
- The filing has a part on tax disputes
- No
- There was a cyber security incident in the quarter
- No
The company's own answers in its filing.
How money raised was used
Reported for the quarter to Jun 2026. A preferential issue sells new shares to chosen investors rather than to the public. A warrant or partly paid issue plans the whole issue while the money comes in over time, so the amount set aside can be more than raised so far.
| Raised | Amount raised | For | Set aside | Spent | Spent elsewhere |
|---|---|---|---|---|---|
| Preferential IssuesApr 2026 | 17.50 | – | – | No |